Triptorelin

FDA-approved context Hormonal Health 3 sources

Triptorelin is a synthetic decapeptide agonist analog of gonadotropin-releasing hormone (GnRH). It initially stimulates but subsequently downregulates pituitary GnRH receptors, leading to a profound suppression of sex hormones. It is widely researched and utilized in clinical settings for hormone-dependent conditions like advanced prostate cancer, endometriosis, and central precocious puberty.

01Dosing reference

Amount

3.75 mg (1-month depot), 11.25 mg (3-month depot), or 22.5 mg (6-month depot)

Frequency

Every 1, 3, or 6 months depending on formulation

Cycle

Continuous use as directed by a physician for chronic conditions

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GnRH receptor binding

Triptorelin binds to GnRH receptors in the anterior pituitary gland with higher affinity and a longer half-life than natural GnRH.

Initial stimulation and subsequent downregulation

It initially stimulates the release of LH and FSH (causing a hormone 'flare'), but continuous exposure causes GnRH receptor downregulation and desensitization.

Medical castration

The drastic drop in gonadotropins halts the production of testosterone and estrogen, creating a therapeutically beneficial hormone-suppressed state.

03Human evidence

Effective in achieving medical castration in advanced prostate cancer.

Numerous large-scale clinical trials have demonstrated that depot formulations of triptorelin reduce serum testosterone to castrate levels within 2-4 weeks, maintaining this suppression long-term.

Significant reduction in endometriosis-associated pain and lesion size.

Clinical studies in women with endometriosis show that triptorelin-induced hypoestrogenism effectively relieves pelvic pain and reduces endometrial implants, though bone mineral density loss limits long-term use.

04Preclinical evidence

Higher potency and longer half-life than native GnRH.

Animal models and in vitro studies showed that the substitution of D-tryptophan at position 6 increases resistance to enzymatic degradation, making it roughly 100-fold more potent than natural GnRH.

Direct anti-proliferative effects on certain cancer cells.

In vitro studies on human prostate and breast cancer cell lines suggest triptorelin may exert direct growth-inhibitory effects mediated by local GnRH receptors, independent of pituitary suppression.

05What is known vs. unknown

Reasonably established

Triptorelin is a highly potent GnRH agonist used to suppress sex hormone production.
It causes an initial 'flare' of hormones before inducing a state of medical castration or menopause.
It is FDA-approved for advanced prostate cancer, central precocious puberty, and sometimes used for endometriosis.
Long-acting depot formulations allow for convenient dosing every 1, 3, or 6 months.

Unknowns & limits

The exact clinical significance of direct peripheral GnRH receptor binding in tumor tissues remains partially understood.
Long-term use is limited by side effects of profound hormone deficiency, such as osteoporosis and cardiovascular risks.

06Safety & regulatory context

Regulatory statusTriptorelin is an FDA-approved prescription medication. Common side effects are related to hormone suppression, including hot flashes, decreased libido, erectile dysfunction, bone mineral density loss, and mood changes. The initial 'flare' effect can temporarily worsen symptoms of prostate cancer (e.g., bone pain or spinal cord compression), often requiring concurrent antiandrogen therapy during the first few weeks. It is contraindicated in pregnancy.

07Compared with Leuprolide

Triptorelin vs. Leuprolide

Key difference

Both are GnRH agonists with similar efficacy, but they differ slightly in their amino acid substitutions (Triptorelin has D-Trp at position 6, Leuprolide has D-Leu at position 6).

When researchers discuss each

They are often discussed interchangeably in the context of androgen deprivation therapy, with the choice usually depending on formulation availability, cost, and specific clinical indications.

08Glossary

GnRH (Gonadotropin-Releasing Hormone)

A hormone produced in the hypothalamus that stimulates the pituitary gland to release LH and FSH.

Medical Castration

The use of drugs to reduce testosterone or estrogen to levels typically seen after surgical removal of the testicles or ovaries.

Downregulation

The process by which a cell decreases the quantity of a cellular component, such as a receptor, in response to continuous stimulation.

09Knowledge check

Q1What is the primary mechanism by which continuous triptorelin administration lowers testosterone levels?

Q2Why might a patient experience a temporary worsening of symptoms when first starting triptorelin?

Q3Which interpretation is best supported by the dossier’s preclinical finding that triptorelin showed direct anti-proliferative effects on certain cancer cell lines in vitro?

Q4According to the dossier, which statement best reflects how researchers typically frame the choice between triptorelin and leuprolide?

Q5Which safety or regulatory practice is directly supported by the dossier when initiating triptorelin in patients with advanced prostate cancer?

10Sources

More in Hormonal Health

See all

Kisspeptin-10

Hormonal Health

Human clinical

Kisspeptin-10 is a potent neuropeptide that acts as an upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Research shows it stimulates the release of gonadotropin-releasing hormone (GnRH), subsequently increasing luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. It is heavily studied for its potential in treating infertility, hypogonadism, and reproductive disorders.

100-300 mcg per dose

Gonadorelin

Hormonal Health

FDA-approved context

Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH). It stimulates the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the gonads to produce testosterone and sperm in males, and estrogen and eggs in females.

100-200 mcg per dose

hCG (Human Chorionic Gonadotropin)

Hormonal Health

FDA-approved context

hCG is a hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) in the body. In research and clinical settings, it is widely used to stimulate testosterone production, preserve fertility, and treat hypogonadism in men, as well as to induce ovulation in women.

250-500 IU

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.